These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7741147)
1. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Warrier I; Kasper CK; White GC; Shapiro AD; Bergman GE Am J Hematol; 1995 May; 49(1):92-4. PubMed ID: 7741147 [TBL] [Abstract][Full Text] [Related]
2. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035 [TBL] [Abstract][Full Text] [Related]
3. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403 [TBL] [Abstract][Full Text] [Related]
4. Safety and recovery of mononine in multiple-dose, high-dose regimens. White GC Acta Haematol; 1995; 94 Suppl 1():53-7; discussion 57-8. PubMed ID: 7571996 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Kim HC; McMillan CW; White GC; Bergman GE; Saidi P Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776 [TBL] [Abstract][Full Text] [Related]
8. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates. Negrier C; Vial J; Vinciguerra C; Berruyer M; Dechavanne M Am J Hematol; 1995 Feb; 48(2):120-4. PubMed ID: 7847325 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate. Kim HC; Matts L; Eisele J; Czachur M; Saidi P Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766 [No Abstract] [Full Text] [Related]
10. Biochemical and in vivo properties of high purity factor IX concentrates. Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433 [TBL] [Abstract][Full Text] [Related]
12. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061 [TBL] [Abstract][Full Text] [Related]
14. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Menache D; Behre HE; Orthner CL; Nunez H; Anderson HD; Triantaphyllopoulos DC; Kosow DP Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Shapiro AD; White Ii GC; Kim HC; Lusher JM; Bergman GE Haemophilia; 1997 Oct; 3(4):247-53. PubMed ID: 27214859 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patients. Ménart C; Petit PY; Attali O; Massignon D; Dechavanne M; Négrier C Am J Hematol; 1998 Jun; 58(2):110-6. PubMed ID: 9625577 [TBL] [Abstract][Full Text] [Related]
17. Preparation and properties of a therapeutic factor IX concentrate. Suomela H; Myllylä G; Raaska E Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244 [TBL] [Abstract][Full Text] [Related]
18. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies. Mauser-Bunschoten EP; Kleine Budde I; Lopaciuk S; Koopman MM; Van Der Meer FJ; Novàkovà IR; Ypma P; Van Der Linden PW; Windyga J; Strengers PF Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109 [TBL] [Abstract][Full Text] [Related]
19. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B. Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218 [TBL] [Abstract][Full Text] [Related]
20. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Feldman F; Chandra S; Huang C Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]